Information Provided By:
Fly News Breaks for May 22, 2018
BMRN
May 22, 2018 | 11:45 EDT
Jefferies analyst Eun Yang said BioMarin's updated Phase 1/2 data for valrox for hemophilia A showed a decline in F8 levels at two years compared to 1.5 years, but she typified the results as showing "continuing strong efficacy" and noted the company seems confident of entering a stable expression phase. The company also announced a modification to its ongoing GENEr8-1 Phase 3 trial to show superiority versus the current standard of care, which raises the bar for efficacy but also for potential clinical risks, though the change supports the company's commercial rationale, said Yang, who keeps her Buy rating and $116 price target on BioMarin shares.
News For BMRN From the Last 2 Days
There are no results for your query BMRN